Clinical Data — J. P. Morgan Healthcare Conference 2011
27 slides from Clinical Data's conference presentation, Jan 12, 2011

Slide 1: J. P. Morgan Healthcare Conference January 12, 2011
J. P. Morgan Healthcare Conference January 12, 2011 1

Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking information and statements that are intended to be covered by the safe harbor for "forward looking" statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not

Slide 3: Clinical Data, Inc. at a Glance
Clinical Data, Inc. at a Glance Completed transformation into a pharmaceutical company with two late-stage drug candidates that address large markets Vilazodone: a serotonin 1A receptor partial agonist and reuptake inhibitor in development for the treatment of depression Stedivaze: potential best-in

Slide 4: Depression Market Remains Large and Unsatisfied
Depression Market Remains Large and Unsatisfied $12 billion U.S. market and growing1 Majority of patients do not achieve success with first therapy2 Side effects are common, e.g., gastrointestinal, sexual function, CNS disorders, and weight gain Co-morbid conditions often require additional medicati

Slide 5: Vilazodone: A Serotonin 1A Receptor Partial Agonist and Reuptake Inhibitor
Vilazodone: A Serotonin 1A Receptor Partial Agonist and Reuptake Inhibitor 5 Blocks serotonin reuptake Binds with high affinity to 5-HT1A auto- and hetero-receptors, Down-regulates 5-HT1A auto-receptors Richardson-Jones JW et al. Neuron. 2010;65:40-52

Slide 6: Vilazodone Demonstrated Superiority to Placebo in Two Phase III Trials
2nd Phase III Vilazodone N = 231 Placebo N = 231 MADRS (primary) - -13.3 - -10.8 - -2.5 0.009 HAMD17 - -10.7 - -9.1 - -1.6 0.026 HAMA - -7.0 - -5.7 - -1.2 0.037 Vilazodone Demonstrated Superiority to Placebo in Two Phase III Trials1 Endpoints Least Squares Mean Change at Week 8 LS Mean Treatment Dif

Slide 7: Findings from Long-term Safety Study (LTSS)
Findings from Long-term Safety Study (LTSS) Consistent with Phase III, Placebo-Controlled Trials Improvement Weeks Receiving Treatment 1Observed cases analysis (scores for 254 patients who remained in the study). N = 596 in effectiveness population. Data on file with Clinical Data, Inc. MADRS scores

Slide 8: Vilazodone Was Generally Well Tolerated in Phase III Trials and LTSS
Vilazodone Was Generally Well Tolerated in Phase III Trials and LTSS Most common adverse events in Phase III trials were diarrhea, nausea, and insomnia1 Most were mild or moderate in intensity and did not require treatment No single adverse event led to discontinuation in >1% of patients No effects

Slide 9: Extended Intellectual Property Protection for Vilazodone
Extended Intellectual Property Protection for Vilazodone U.S. Composition of Matter patent expires in 2014 5-year extension anticipated via Hatch-Waxman providing protection into 2019 Newly U.S. issued patent for most commercially viable polymorphic form extends protection for ~3 more years to 2022

Slide 10: Market Dynamics in Treatment of Depression Are Changing
Market Dynamics in Treatment of Depression Are Changing Only one currently branded depression drug may be on the market beyond 2014 Brand promotion is decreasing in historically promotionally sensitive category Targeted approaches and smaller sales forces are becoming more common Market is awaiting

Slide 11: Brands Continue to Thrive
Brands Continue to Thrive 11 Source: IMS HEALTH'S National Sales Perspective

Slide 12: Highly Concentrated U.S. Prescriber Market is Readily Accessible
Market Decile Cum. % of Prescribers Cum. % of TRx 10 0.5% 10.0% 9 1.5% 20.0% 8 2.9% 30.0% 7 4.7% 40.0% 6 6.8% 50.0% 5 9.5% 60.0% 4 12.8% 70.0% 3 17.5% 80.0% 2 25.3% 90.0% 1 100.0% 100.0% 9 8 7 6 5 4 3 2 1 Highly Concentrated U.S. Prescriber Market is Readily Accessible < 7% of prescribers account fo

Slide 13: Revenue Opportunity Remains Large in Depression Market
Revenue Opportunity Remains Large in Depression Market Market Decile Cum. % of Prescribers 5% Share of TRx (000's) 10% Share of TRx (000's) 10 0.5% $ 158,250 $ 316,500 9 1.5% $ 316,500 $ 633,000 8 2.9% $ 474,750 $ 949,500 7 4.7% $ 633,000 $1,266,000 6 6.8% $ 791,250 $1,582,500 5 9.5% $ 949,500 $1,89

Slide 14: Positioned for Commercialization Upon Approval
Positioned for Commercialization Upon Approval 14

Slide 15: Medical Education Activities Ongoing
Medical Education Activities Ongoing Advisory Board meetings and interactions with KOLs continues Implementing fully integrated publication plan: 27 abstracts published to date 19 manuscripts to date 16 posters presented at major medical/HCP meetings in 2010 ~20 abstracts/posters projected in 2011;

Slide 16: Managed Care Markets Communications Underway
Managed Care Markets Communications Underway Conducted payer landscape assessment and segmentation Developed and validated managed markets messages Producing vilazodone AMCP formulary dossier Began market shaping campaign with first of a series of advertorials introduced 16

Slide 17: Sales Force Development and Projected Launch
Sales Force Development and Projected Launch Top level sales and marketing management team on board Key sales force candidates identified, interviewed and contingent offer letters ready upon approval 150 sales representatives targeting high prescribers accounting for approximately 30% of U.S. MDD pr

Slide 18: Stedivaze for Cardiac Stress Testing
Stedivaze for Cardiac Stress Testing Potential best-in-class coronary vasodilator for myocardial perfusion imaging (MPI) Adenosine 2A receptor agonist in Phase III development Positive attributes position Stedivaze to be potential best-in-class Superior adenosine 2A receptor binding selectivity Pote

Slide 19: Stedivaze Demonstrates Superior Adenosine2A Receptor Binding Selectivity
Stedivaze Demonstrates Superior Adenosine2A Receptor Binding Selectivity Adenosine A1 A2B A3 A2A selective agonist A2A Coronary vasodilation Peripheral vasodilation Anti-inflammatory A-V heart block Bradycardia Chest pain Peripheral vasodilation Bronchiolar constriction Mast cell degranulation *Resu

Slide 20: Stedivaze Phase III ASPECT
Stedivaze Phase III ASPECT 1 First of two Phase III trials: Apadenoson Single Photo Emission Computed Tomography (ASPECT) Objective is to establish comparable efficacy and superior tolerability compared to adenosine N=750 patients over 18-24 months Patients undergo SPECT MPI, then are randomized to

Slide 21: Pharmacologic SPECT-MPI Market Continues to Grow
21 Pharmacologic SPECT-MPI Market Continues to Grow U.S. Market Projected to be $800M in 20111 Sources: 1996-2008 data provided by Clinical Data to Third Party . 2008 data scaled from 2H 2009 data, and 2009 data scaled from 1H 2009 data, AMR. The Myocardial Perfusion Study Market Guide, Jul - Dec 20

Slide 22: Intellectual Property Protection for Stedivaze Anticipated Through 2024
Intellectual Property Protection for Stedivaze Anticipated Through 2024 U.S. Composition of Matter and Method of Use patents expire in 2019 Anticipate 5-year extension through Hatch-Waxman providing protection into 2024 Activities to secure additional patents is well underway with several patents pe

Slide 23: PRX-8066 in Phase II Development for PAH
PRX-8066 in Phase II Development for PAH Selective serotonin 2B (5-HT2B) receptor antagonist with potential for disease modification 5-HT2B receptors regulate abnormal cell growth and proliferation in the pulmonary vasculature of PAH patients Granted Orphan Drug Designation from FDA for Pulmonary Ar

Slide 24: Clinical Data Drugs in Development
24 Vilazodone: Depression Pain Oncology: B-cell Cancers 1222: Acute Inflammation 8066: Pulmonary Arterial Hypertension (PAH) 844: Diabetes Asthma 313: Glaucoma Stedivaze: Cardiac Stress Testing Novartis Option Santen, IND filed 12/10 Zalicus* Granted Orphan Drug Status Nov 2010 PDUFA Date of January

Slide 25: Clinical Data, Inc. (CLDA) Financial Summary
Clinical Data, Inc. (CLDA) Financial Summary 1 At September 30, 2010 2 Shown at face value and convertible at $8.18 per share; held by Randal J. Kirk and his affiliates 3 At November 5, 2010 4 Proceeds from sale of genetic testing unit sale to Transgenomic’, announced December 29, 2010 5 Escrow proc

Slide 26: Investment Highlights
Investment Highlights Two late-stage products target large and growing markets: vilazodone and Stedivaze Near-term events Potential approval of vilazodone: PDUFA date January 22, 2011 2nd Phase III Stedivaze trial to begin in 1H 2011 IND on at least one of several pipeline programs Multiple partners

Slide 27: Clinical Data
CLINICAL? DATA’
Source: SEC EDGAR · 8-K filed Jan 12, 2011
More decks from Clinical Data Inc
Technical Presentation (May 2010)10 slides · May 25, 2010
Rodman & Renshaw Global Investment Conference 200924 slides · Sep 9, 2009
BMO Capital Markets Focus on Healthcare Conference 200930 slides · Aug 5, 2009
Fifth Annual Noble Financial Equity Conference 200923 slides · Jun 9, 2009
Investor Presentation (January 2009)25 slides · Jan 12, 2009
BMO Capital Markets Focus On Healthcare Conference 200833 slides · Aug 5, 2008